NorthWest Biotherapeutics Inc (NWBO)

[GPha]

My post gonna be partially irrelevant since ex answered your inquiry. I'm giving a piece of extra information for anyone who could benefit from it regarding the nomenclature of biologics specially targeted monoclonal antibodies, especially for oncology purposes.

If it contains substem "ci" then it's targeting the circulatory system for example Bevacizumab and Ramucirumab.
If the substem was "tu" then it targets the tumor examples are many here such as Cetuximab, Trastuzumab, Pertuzumab, Panitumumab, Inotuzumab, etc...
If the substem was "li" then it targets the immune system for example Ipilimumab, Nivolumab, Atezolizumab, and our friend Pembrolizumab.

Another information mab is the suffix that monoclonal antibodies share but the letters before it refers to the origin of the antibody itself. For xi (Infliximab)means the origin was the chimeric origin. While zu (Palivizumab) means it's of humanized origin. lastly, u (Golimumab) means it's from human origin.
by origin, we don't mean we take from a living human we modify the cells in long process not gonna get into the details of it.
hopefully, anyone can utilize this information to guide him through the world of biotech.